CAMBRIDGE, Mass., Jan. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today ...

Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 ...

Jessica Apanowicz — Ansonia, Sr., All-NVL 2nd Team: Apanowicz specialized on the defensive end of the field last year as a center back, but can also play midfield and forward. Giuliana Celotto — ...

Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment ...

Nuvalent, Inc., a clinical-stage biopharmaceutical company, announced the initiation of the phase 2 portion of ALKOVE-1, its phase 1/2 clinical trial of NVL-655 for patients with ALK-positive ...

NVL-655 is a novel, brain-penetrant, ALK-selective tyrosine kinase inhibitor (TKI) developed to address emergent treatment resistance and brain metastases while minimizing off-target central nervous ...

Wylden Abraham — Shepaug, Sr.: Just missed out on All-BL accolades with a 10th-place finish at the league meet. Reide Augustyn — Lakeview, Sr.: The second-fastest Bobcat behind Ben Schildgen, he was ...

CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

At Supercomputing 2024, the AI computing giant shows off what is likely its biggest AI ‘chip’ yet—the four-GPU Grace Blackwell GB200 NVL4 Superchip—while it announces the general availability of its ...

Nvidia Corp. today announced the availability of its newest data center-grade graphics processing unit, the H200 NVL, to power artificial intelligence and high-performance computing. The company ...